122 related articles for article (PubMed ID: 26584950)
1. Sulphonylurea receptor-1, sulphonylureas and amplification of insulin secretion by Epac activation in β cells.
Nenquin M; Henquin JC
Diabetes Obes Metab; 2016 Jul; 18(7):698-701. PubMed ID: 26584950
[TBL] [Abstract][Full Text] [Related]
2. Activators of PKA and Epac distinctly influence insulin secretion and cytosolic Ca2+ in female mouse islets stimulated by glucose and tolbutamide.
Henquin JC; Nenquin M
Endocrinology; 2014 Sep; 155(9):3274-87. PubMed ID: 24977470
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components.
Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH
Pharmacol Res; 2004 Jul; 50(1):41-6. PubMed ID: 15082027
[TBL] [Abstract][Full Text] [Related]
4. Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca2+ in pancreatic B-cells.
Garcia-Barrado MJ; Jonas JC; Gilon P; Henquin JC
Eur J Pharmacol; 1996 Mar; 298(3):279-86. PubMed ID: 8846827
[TBL] [Abstract][Full Text] [Related]
5. cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells.
Kang G; Chepurny OG; Malester B; Rindler MJ; Rehmann H; Bos JL; Schwede F; Coetzee WA; Holz GG
J Physiol; 2006 Jun; 573(Pt 3):595-609. PubMed ID: 16613879
[TBL] [Abstract][Full Text] [Related]
6. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.
Zhang CL; Katoh M; Shibasaki T; Minami K; Sunaga Y; Takahashi H; Yokoi N; Iwasaki M; Miki T; Seino S
Science; 2009 Jul; 325(5940):607-10. PubMed ID: 19644119
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of ß-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac.
Leech CA; Dzhura I; Chepurny OG; Schwede F; Genieser HG; Holz GG
Islets; 2010; 2(2):72-81. PubMed ID: 20428467
[TBL] [Abstract][Full Text] [Related]
8. Treating diabetes today: a matter of selectivity of sulphonylureas.
Seino S; Takahashi H; Takahashi T; Shibasaki T
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705
[TBL] [Abstract][Full Text] [Related]
9. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
McClenaghan NH; Flatt PR; Ball AJ
J Endocrinol; 2006 Sep; 190(3):889-96. PubMed ID: 17003289
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between cAMP signalling and sulfonylurea in insulin secretion.
Shibasaki T; Takahashi T; Takahashi H; Seino S
Diabetes Obes Metab; 2014 Sep; 16 Suppl 1():118-25. PubMed ID: 25200305
[TBL] [Abstract][Full Text] [Related]
11. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content.
Anello M; Gilon P; Henquin JC
Br J Pharmacol; 1999 Aug; 127(8):1883-91. PubMed ID: 10482920
[TBL] [Abstract][Full Text] [Related]
12. Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs.
Tsalkova T; Gribenko AV; Cheng X
Assay Drug Dev Technol; 2011 Feb; 9(1):88-91. PubMed ID: 21133673
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP-sensitive K+ channels.
Szollosi A; Nenquin M; Henquin JC
Br J Pharmacol; 2010 Feb; 159(3):669-77. PubMed ID: 20128805
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.
Jarrard RE; Wang Y; Salyer AE; Pratt EP; Soderling IM; Guerra ML; Lange AM; Broderick HJ; Hockerman GH
Mol Pharmacol; 2013 Jan; 83(1):191-205. PubMed ID: 23071106
[TBL] [Abstract][Full Text] [Related]
15. Phospholipase C-ε links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans.
Dzhura I; Chepurny OG; Leech CA; Roe MW; Dzhura E; Xu X; Lu Y; Schwede F; Genieser HG; Smrcka AV; Holz GG
Islets; 2011; 3(3):121-8. PubMed ID: 21478675
[TBL] [Abstract][Full Text] [Related]
16. β-Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion.
Barella LF; Rossi M; Zhu L; Cui Y; Mei FC; Cheng X; Chen W; Gurevich VV; Wess J
J Clin Invest; 2019 Jun; 129(9):3732-3737. PubMed ID: 31184597
[TBL] [Abstract][Full Text] [Related]
17. Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.
Yosida M; Dezaki K; Uchida K; Kodera S; Lam NV; Ito K; Rita RS; Yamada H; Shimomura K; Ishikawa SE; Sugawara H; Kawakami M; Tominaga M; Yada T; Kakei M
Diabetes; 2014 Oct; 63(10):3394-403. PubMed ID: 24824430
[TBL] [Abstract][Full Text] [Related]
18. Interaction between Munc13-1 and RIM is critical for glucagon-like peptide-1 mediated rescue of exocytotic defects in Munc13-1 deficient pancreatic beta-cells.
Kwan EP; Xie L; Sheu L; Ohtsuka T; Gaisano HY
Diabetes; 2007 Oct; 56(10):2579-88. PubMed ID: 17639022
[TBL] [Abstract][Full Text] [Related]
19. Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane.
Schwanstecher M; Schwanstecher C; Dickel C; Chudziak F; Moshiri A; Panten U
Br J Pharmacol; 1994 Nov; 113(3):903-11. PubMed ID: 7858884
[TBL] [Abstract][Full Text] [Related]
20. Nuciferine stimulates insulin secretion from beta cells-an in vitro comparison with glibenclamide.
Nguyen KH; Ta TN; Pham TH; Nguyen QT; Pham HD; Mishra S; Nyomba BL
J Ethnopharmacol; 2012 Jul; 142(2):488-95. PubMed ID: 22633982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
